Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King TA, Mittendorf EA, Curigliano G, Hughes ME, Stover DG, Tolaney SM, Weeks LD, Tayob N, Lin NU, Garber JE, Miller PG, Parsons HA. Morganti S, et al. J Clin Oncol. 2024 Nov;42(31):3666-3679. doi: 10.1200/JCO.23.01071. Epub 2024 Jan 8. J Clin Oncol. 2024. PMID: 38190580
What therapies are on the horizon for HER2 positive breast cancer?
Viale G, Morganti S, Ferraro E, Zagami P, Marra A, Curigliano G. Viale G, et al. Among authors: morganti s. Expert Rev Anticancer Ther. 2019 Sep;19(9):811-822. doi: 10.1080/14737140.2019.1660164. Epub 2019 Aug 28. Expert Rev Anticancer Ther. 2019. PMID: 31448640 Review.
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Mazzarella L, et al. Among authors: morganti s. J Immunother Cancer. 2020 Mar;8(1):e000475. doi: 10.1136/jitc-2019-000475. J Immunother Cancer. 2020. PMID: 32238471 Free PMC article. Review.
HER2-Low Breast Cancer: Pathological and Clinical Landscape.
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. Tarantino P, et al. Among authors: morganti s. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. J Clin Oncol. 2020. PMID: 32330069 Review. No abstract available.
Margetuximab for the treatment of HER2-positive metastatic breast cancer.
Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Tarantino P, et al. Among authors: morganti s. Expert Opin Biol Ther. 2021 Feb;21(2):127-133. doi: 10.1080/14712598.2021.1856812. Epub 2020 Dec 14. Expert Opin Biol Ther. 2021. PMID: 33238772 Free article. Review.
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis.
Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, Criscitiello C, Curigliano G. Esposito A, et al. Among authors: morganti s. Eur J Cancer. 2021 Mar;145:197-209. doi: 10.1016/j.ejca.2020.12.028. Epub 2021 Jan 22. Eur J Cancer. 2021. PMID: 33493979
368 results